Difference between revisions of "Part:BBa K3183200"
(→Part Improvement of BBa_K895004) |
(→Part Improvement of BBa_K895004) |
||
| Line 46: | Line 46: | ||
[[File:BBa_K3183200_Construct_Oxford.png|thumb|right|455px|'''Figure 1.2:''' 6His-SpyTag-CD27L Construct in pET28A]] | [[File:BBa_K3183200_Construct_Oxford.png|thumb|right|455px|'''Figure 1.2:''' 6His-SpyTag-CD27L Construct in pET28A]] | ||
<br><br> | <br><br> | ||
| − | Thus, we sought out the endolysin in an existing part made by the 2012 iGEM Team Dundee. However, despite identical growth and induction conditions, expression of the Dundee 2012 iGEM endolysin was unsuccessful, even in triplicate, as shown in Figure 1. In contrast, expression of the CD27L_Assay part was successful and quantitatively verified via both mass spectrometry and BCA assay, as in the Results page.<br><br><br><br> | + | Thus, we sought out the endolysin in an existing part made by the 2012 iGEM Team Dundee. However, despite identical growth and induction conditions, expression of the Dundee 2012 iGEM endolysin was unsuccessful, even in triplicate, as shown in Figure 1. In contrast, expression of the CD27L_Assay part was successful and quantitatively verified via both mass spectrometry and BCA assay, as in the Results page.<br><br> |
| + | [[File:BBa K895004 Expression Gel.png|thumb|right|700px|'''Figure 2:'''Dundee CD27L<sub>1-179</sub> Expression Gel]] | ||
| + | <br><br> | ||
Thus, to solve this issue, we decided to attempt expression of only the truncated endolysin from the Dundee 2012 Biobrick, without its substantially large Type VI secretion tag. This resulted in BBa_K31830012 (CD27L_Truncated 1-179). Upon analysis, there is evident expression of the truncated endolysin as seen in Figure 2. However, given identical conditions of growth and induction, there appears to be greater expression of the full-length endolysin, which may perhaps indicate greater stability.<br><br> | Thus, to solve this issue, we decided to attempt expression of only the truncated endolysin from the Dundee 2012 Biobrick, without its substantially large Type VI secretion tag. This resulted in BBa_K31830012 (CD27L_Truncated 1-179). Upon analysis, there is evident expression of the truncated endolysin as seen in Figure 2. However, given identical conditions of growth and induction, there appears to be greater expression of the full-length endolysin, which may perhaps indicate greater stability.<br><br> | ||
| − | [[File: | + | [[File:BBa_K31830012_Purification_Gel.png|thumb|right|700px|'''Figure 3:''' CD27L<sub>1-179</sub> Purification Gel]] |
<br> | <br> | ||
<br> | <br> | ||
As a further improvement, we decided to measure the killing efficacy of the CD27L_Assay endolysin on B. subtilis (our surrogate target) as no killing data was provided for the Dundee 2012 BBa_K895005 part. As seen in Figure 3, there is a substantial decrease in OD600 over time relative to the negative controls.<br><br> | As a further improvement, we decided to measure the killing efficacy of the CD27L_Assay endolysin on B. subtilis (our surrogate target) as no killing data was provided for the Dundee 2012 BBa_K895005 part. As seen in Figure 3, there is a substantial decrease in OD600 over time relative to the negative controls.<br><br> | ||
| − | |||
Revision as of 21:43, 19 October 2019
CD27L with N-Terminal 6-His Tag and SpyTag
CD27L with N-Terminal 6-His Tag and SpyTag
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Characterisation
Part Improvement of BBa_K895004
A fundamental crux of the ProQuorum system is the expression of the endolysin which is responsible for the actual lysis and consequent killing of the pathogenic C. difficile. Thus, there is a clear need for an endolysin that fulfills the criteria of being:
1. optimally expressed
2. optimally secreted and
3. optimally effective against C.difficile
Thus, we redesigned the BBa_K895005 part submitted by the 2012 Dundee iGEM team, which consists of:
1. truncated form of the CD27L endolysin, shown to increase both efficacy and host range2
2. Type VI secretion protein derived from S. typhimurium
3. Hemagglutinin (HA) Tag for Western Blotting
In contrast, our novel part BBa_K3183009 (CD27L) encodes:
1. full-length form of the CD27L endolysin
2. SpyTag for purification, oligomerisation, and other SpyCatcher applications
3. 6-His tag for easy purification
Incorporating both of these parts into pET28A, our expression vector, we planned on testing the relative efficacies of B.subtilis killing as per our killing assays. Thus, we followed our generic pipeline of:
1. transformation of both constructs into E.coli (BL21 (DE3)-RIPL Competent E.coli)
2. miniprep + sequencing to verify successful transformation
3. induction of expression with IPTG
Thus, we sought out the endolysin in an existing part made by the 2012 iGEM Team Dundee. However, despite identical growth and induction conditions, expression of the Dundee 2012 iGEM endolysin was unsuccessful, even in triplicate, as shown in Figure 1. In contrast, expression of the CD27L_Assay part was successful and quantitatively verified via both mass spectrometry and BCA assay, as in the Results page.
Thus, to solve this issue, we decided to attempt expression of only the truncated endolysin from the Dundee 2012 Biobrick, without its substantially large Type VI secretion tag. This resulted in BBa_K31830012 (CD27L_Truncated 1-179). Upon analysis, there is evident expression of the truncated endolysin as seen in Figure 2. However, given identical conditions of growth and induction, there appears to be greater expression of the full-length endolysin, which may perhaps indicate greater stability.
As a further improvement, we decided to measure the killing efficacy of the CD27L_Assay endolysin on B. subtilis (our surrogate target) as no killing data was provided for the Dundee 2012 BBa_K895005 part. As seen in Figure 3, there is a substantial decrease in OD600 over time relative to the negative controls.